30923-69-4

Basic information

• Product Name: 1-cyclopropyl-4,4,4-trifluoro-1,3-butanedione
• Synonyms: 1-cyclopropyl-4,4,4-trifluoro-1,3-butanedione
• CAS NO: 30923-69-4
• Molecular Formula: C₇H₇F₃O₂
• Molecular Weight: 180.13
• Mol File: 30923-69-4.mol
• Article Data: 9

Chemical Properties

• Boiling Point: 178.4°C at 760 mmHg
• Flash Point: 55°C
• Appearance: /
• Density: 1.374g/cm³
• Vapor Pressure: 0.992mmHg at 25°C
• Refractive Index: 1.414
• Storage Temp.: under inert gas (nitrogen or Argon) at 2-8°C
• PKA: 6?+-.0.20(Predicted)
• CAS DataBase Reference: 1-cyclopropyl-4,4,4-trifluoro-1,3-butanedione(CAS DataBase Reference)
• NIST Chemistry Reference: 1-cyclopropyl-4,4,4-trifluoro-1,3-butanedione(30923-69-4)
• EPA Substance Registry System: 1-cyclopropyl-4,4,4-trifluoro-1,3-butanedione(30923-69-4)

Safety Data

• HazardClass: IRRITANT
• Hazardous Substances Data: 30923-69-4(Hazardous Substances Data)

Usage

General Description

1-Cyclopropyl-4,4,4-trifluoro-1,3-butanedione is a chemical compound that consists of a cyclopropyl group attached to a butanedione molecule with three fluorine atoms. It is commonly used as a reagent in organic synthesis and as a building block for the preparation of various compounds. 1-cyclopropyl-4,4,4-trifluoro-1,3-butanedione is known for its strong electrophilic nature, which makes it useful in the formation of carbon-carbon and carbon-heteroatom bonds. Additionally, it has been used in the development of pharmaceuticals, agrochemicals, and other functional materials. Its unique structure and reactivity make it a valuable tool in the field of organic chemistry for the creation of complex molecules.

InChI:InChI=1/C7H7F3O2/c8-7(9,10)6(12)3-5(11)4-1-2-4/h4H,1-3H2

Upstream product

• 765-43-5 Cyclopropyl methyl ketone 
• 383-63-1 ethyl trifluoroacetate, 
• 431-47-0 trifluoroacetic acid-methyl ester 

Downstream Products

• 1062295-85-5 3-cyclopropyl-5-(trifluoromethyl)-1H-pyrazole 
• 1057659-67-2 C₁₃H₁₁N₂F₃ 
• 1057659-71-8 4-bromo-5-cyclopropyl-3-trifluoromethyl-1-phenylpyrazole 
• 1057659-72-9 4-bromo-5-cyclopropyl-3-trifluoromethylpyrazole 
• 1288342-17-5 N-{4-[4-chloro-5-cyclopropyl-3-(trifluoromethyl)-1H-pyrazol-1-yl]-3-fluorophenyl}-4-methylpyrimidine-5-carboxamide 
• 1288342-18-6 N-{4-[4-chloro-5-cyclopropyl-3-(trifluoromethyl)-1H-pyrazol-1-yl]phenyl}-3-oxobutanamide 
• 1288342-19-7 N-{4-[4-chloro-5-cyclopropyl-3-(trifluoromethyl)-1H-pyrazol-1-yl]phenyl}-2-[(dimethylamino)methylene]-3-oxobutanamide 
• 1288342-30-2 N-{4-[5-cyclopropyl-3-(trifluoromethyl)-1H-pyrazol-1-yl]-3,5-difluorophenyl}-4-methylpyrimidine-5-carboxamide 
• 1288342-31-3 N-{4-[5-cyclopropyl-3-(trifluoromethyl)-1H-pyrazol-1-yl]-3,5-difluorophenyl}-3-oxobutanamide 
• 1288342-32-4 N-{4-[5-cyclopropyl-3-(trifluoromethyl)-1H-pyrazol-1-yl]-3,5-difluorophenyl}-2-[(dimethylamino)methylene]-3-oxobutanamide 
• 1318763-41-5 5-cyclopropyl-1-(2-fluoro-4-nitrophenyl)-3-(trifluoromethyl)-1H-pyrazole 
• 1288340-45-3 5-cyclopropyI-1-(2,6-difluoro-4-nitrophenyl)-3-(trifluoromethyl)-1H-pyrazoIe 
• 1288340-55-5 4-(4-chloro-5-cyclopropyl-3-(trifluoromethyl)-1H-pyrazol-1-yl)-3-fluoroaniline 
• 1288340-56-6 4-(5-cyclopropyl-3-(trifluoromethyl)-1H-pyrazol-1-yl)-3,5-difluoroaniline 

Relevant articles and documents

Discovery and structure-resistance relationship study of new thieno[2,3-b] pyridine HCV NS4B inhibitors

The non-structural protein 4B (NS4B) of hepatitis C virus (HCV) has emerged as a promising target for chronic hepatitis C treatment. The thieno[2,3-b]pyridine HCV inhibitor 2 has demonstrated properties as a NS4B inhibitor. Subsequent hybridization of 2 with our recently published imidazo[2,1-b]thiazole NS4B inhibitor 3 resulted in the discovery of several more potent compounds with sub-micromolar EC50 against HCV genotype 1b replicon. More importantly, the resistant profile study of the new synthesized HCV inhibitors illustrated that the bicyclic scaffold would mediate the resistance of H3R and Q26R mutations, while the piperazinone motif would mediate the resistance of H94R, F98C and V105M mutations, and the C3- amino group would disrupt the interaction between piperazinone motif and NS4B. This structure-resistance relationship detail could help us to develop new NS4B inhibitors with higher resistant barrier in the future.

Discovery of GluN2A-Selective NMDA Receptor Positive Allosteric Modulators (PAMs): Tuning Deactivation Kinetics via Structure-Based Design

The N-methyl-d-aspartate receptor (NMDAR) is a Na+ and Ca2+ permeable ionotropic glutamate receptor that is activated by the coagonists glycine and glutamate. NMDARs are critical to synaptic signaling and plasticity, and their dysfunction has been implicated in a number of neurological disorders, including schizophrenia, depression, and Alzheimer's disease. Herein we describe the discovery of potent GluN2A-selective NMDAR positive allosteric modulators (PAMs) starting from a high-throughput screening hit. Using structure-based design, we sought to increase potency at the GluN2A subtype, while improving selectivity against related α-amino-3-hydroxy-5-methyl-4-isoxazolepropionic acid receptors (AMPARs). The structure-activity relationship of channel deactivation kinetics was studied using a combination of electrophysiology and protein crystallography. Effective incorporation of these strategies resulted in the discovery of GNE-0723 (46), a highly potent and brain penetrant GluN2A-selective NMDAR PAM suitable for in vivo characterization.

THIAZOLOPYRIMIDINONES AS MODULATORS OF NMDA RECEPTOR ACTIVITY

The present invention relates to certain thiazolopyrimidinone compounds for use in modulating NMDA receptor activity, pharmaceutical compositions comprising such compounds and methods of treating neurological and psychiatric conditions.